Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
- 1 January 2014
- journal article
- review article
- Published by Elsevier in Survey of Ophthalmology
- Vol. 59 (1) , 1-18
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007American Journal of Ophthalmology, 2011
- CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degenerationJournal of Ocular Biology, Diseases, and Informatics, 2010
- Norrin, Frizzled-4, and Lrp5 Signaling in Endothelial Cells Controls a Genetic Program for Retinal VascularizationCell, 2009
- Alleles in the HtrA Serine Peptidase 1 Gene Alter the Risk of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degenerationInternational Ophthalmology, 2008
- Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibitionCellular Signalling, 2007
- Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesionsBritish Journal of Ophthalmology, 2007
- Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic reviewBritish Journal of Ophthalmology, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006